Joana Carvalho, PhD, managing science editor —

Joana holds a bachelor’s in biology, a Master of Science in evolutionary and developmental biology, and a PhD in biomedical sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — those that make up the lining of blood vessels — found in the umbilical cord of newborns. In addition to several research fellowships, she was awarded two Erasmus scholarships to conduct part of her studies in France.

Articles by Joana Carvalho

University, CF Athlete Team Up for PhD Research Program

The University of Portsmouth, U.K., is partnering with Josh Llewellyn-Jones, a record-breaking endurance athlete who has cystic fibrosis (CF), to drive a scientific PhD research program that aspires to improve the lives of people with the disease. Llewellyn-Jones defied the odds by living past his 30s and…

Pravibismane, Potential New Antimicrobial Class, Gets 2nd CFF Grant

The Cystic Fibrosis Foundation has given an additional $1.8 million to support early toxicology studies of pravibismane, Microbion’s investigational inhaled therapy for lung infections in people with cystic fibrosis (CF).  Data from these early toxicology studies, expected to conclude by mid-year, could support regulatory requests to…

Inhaled-IV Antibiotic Combo May Better Treat Acute Flares Than IV-only Mix

When given alongside the antibiotic Colistin (colistimethate), Cayston (aztreonam lysine), an inhaled antibiotic specifically targeting Pseudomonas aeruginosa, was superior to standard intravenous antibiotics at improving lung function and life quality among adults with cystic fibrosis (CF) and lung infections due to P. aeruginosa during an acute flare, a single-site…

Arcturus to Develop ARCT-032 as RNA Therapy for CF

Arcturus Therapeutics has selected ARCT-032, an aerosolized RNA-based therapy, to be developed as a novel therapeutic candidate for cystic fibrosis (CF). The therapy will use the company’s LUNAR delivery technology that comprises a library of more than 150 proprietary fatty molecules specifically designed to deliver RNA-based therapies…